List of 10 Genomics Companies Revolutionizing Healthcare in the US

Free List Of Top 10 Genomics Companies

In the fast-evolving world of genomics, numerous companies in the United States are at the forefront of groundbreaking research and development, revolutionizing healthcare with cutting-edge technologies and advancements. The genomics sector is continually pushing the boundaries of medical science, offering hope for enhanced diagnostics, personalized medicine, and targeted therapies for a wide range of diseases. Here, we present an overview of the top 10 genomics companies in the US, including their sector, year founded, annual revenue, short description, and a link to their website.

Illumina, Inc.

Sector: Genomic Sequencing

Year Founded: 1998

Annual Revenue: $3.54 billion (2019)

Description: Illumina is a global leader in genomics and offers a comprehensive portfolio of products and services for genomic analysis. The company’s innovative sequencing and array technologies are used by researchers, clinicians, and pharmaceutical companies worldwide. Illumina plays a pivotal role in driving the integration of genomics into mainstream healthcare.

Website: [Illumina](

Thermo Fisher Scientific, Inc.

Sector: Life Sciences Tools & Services

Year Founded: 2006

Annual Revenue: $25.5 billion (2019)

Description: Thermo Fisher Scientific is a prominent player in the genomics landscape, providing a wide range of products and services for genomic analysis, including sequencing systems, reagents, and bioinformatics solutions. The company’s offerings cater to various aspects of genomics research, from sample preparation to data analysis.

Website: [Thermo Fisher Scientific](

CRISPR Therapeutics

Sector: Gene Editing

Year Founded: 2013

Annual Revenue: $3.1 million (2019)

Description: CRISPR Therapeutics focuses on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing platform. The company’s innovative approach holds the potential to revolutionize the treatment of genetic disorders, cancer, and other complex diseases, offering new hope for patients with unmet medical needs.

Website: [CRISPR Therapeutics](

Pacific Biosciences

Sector: Genomic Sequencing

Year Founded: 2004

Annual Revenue: $102.9 million (2019)

Description: Pacific Biosciences is a pioneer in long-read sequencing technology, enabling researchers to unravel complex genetic variation and genomic structures with unparalleled accuracy. The company’s innovative platforms have broad applications in genomics, including structural variant detection, full-length transcript sequencing, and metagenomics analysis.

Website: [Pacific Biosciences](

Invitae Corporation

Sector: Genetic Testing & Diagnostics

Year Founded: 2010

Annual Revenue: $216.7 million (2019)

Description: Invitae is a leading provider of comprehensive genetic testing and diagnostics, offering a wide array of services for hereditary and somatic genetic testing. The company’s focus on accessibility and affordability has positioned it as a key player in advancing the integration of genetic information into mainstream healthcare and precision medicine.

Website: [Invitae](

10x Genomics, Inc.

Sector: Genomic Analysis

Year Founded: 2012

Annual Revenue: $245.4 million (2019)

Description: 10x Genomics is dedicated to advancing the recognizing of biology at an unprecedented scale with its innovative genomic analysis platforms. The company’s state-of-the-art solutions enable high-resolution insights into single-cell biology, immune profiling, and spatial genomics, empowering researchers to unlock new frontiers in biological discovery.

Website: [10x Genomics](

Guardant Health, Inc.

Sector: Liquid Biopsy & Cancer Diagnostics

Year Founded: 2012

Annual Revenue: $214 million (2019)

Description: Guardant Health specializes in non-invasive cancer screening and monitoring through its proprietary liquid biopsy technologies. The company’s innovative assays and data analysis solutions provide real-time genomic insights, contributing to more accurate cancer detection, treatment selection, and monitoring of treatment response.

Website: [Guardant Health](

Exact Sciences Corporation

Sector: Molecular Diagnostics

Year Founded: 1995

Annual Revenue: $1.41 billion (2019)

Description: Exact Sciences is committed to transforming cancer screening and detection through its non-invasive molecular diagnostics, notably the Cologuard test for colorectal cancer. The company’s innovative solutions harness the power of genomics to improve early cancer detection, driving better patient outcomes and reducing healthcare costs.

Website: [Exact Sciences](

Personalis, Inc.

Sector: Genomic Analysis & Interpretation

Year Founded: 2011

Annual Revenue: $79.8 million (2019)

Description: Personalis specializes in advanced genomic analysis and interpretation, offering comprehensive solutions for cancer immunotherapy, immuno-oncology, and rare genetic diseases. The company’s highly accurate genomic profiling services enable precise identification of therapeutic targets and biomarkers, empowering the development of personalized treatment strategies.

Website: [Personalis](

Genomic Health, Inc.

Sector: Oncotype DX Testing

Year Founded: 2000

Annual Revenue: $394.1 million (2019)

Description: Genomic Health is dedicated to transforming cancer care through its Oncotype DX tests, which provide actionable genomic information to guide treatment decisions for breast, prostate, and colon cancers. The company’s innovative assays assist physicians and patients in making informed choices, leading to more personalized and effective treatment strategies.

Website: [Genomic Health](

The genomics landscape in the United States is marked by a dynamic interplay of research, technological innovation, and commercialization, with these top companies leading the charge in driving transformative advancements in healthcare. As genomics continues to gain momentum in shaping the future of precision medicine and patient care, these companies are poised to play an instrumental role in delivering impactful solutions to address the diverse challenges in healthcare.